Predict your next investment

figo company logo
INTERNET | Internet Software & Services / Accounting & Finance

See what CB Insights has to offer

Founded Year



Series C | Alive

Total Raised


Last Raised

$11.87M | 4 yrs ago

About figo

figo is a banking service provider that makes it easy for businesses to integrate banking functions into their everyday tasks such as automated bookkeeping, simplified credit checks, or account changes.

figo Headquarter Location

Gaußstraße 190c Eingang 2

Hamburg, 22765,


+49 040-22821271

Latest figo News

Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer

Jul 22, 2021

Qianqian Zhang,1,2 Liju Zong,3 Hui Zhang,2 Wei Xie,4 Fan Yang,5 Wenwen Sun,5 Baoxia Cui,1 Youzhong Zhang1 1Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Ji’nan, People’s Republic of China; 2Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, People’s Republic of China; 3Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 4Department of Emergency, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, People’s Republic of China; 5Department of Pathology, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, People’s Republic of China Correspondence: Youzhong Zhang Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Wenhua Xi Road 107#, Jinan, 250012, People’s Republic of China Tel/Fax +86 531-882169268 Purpose: The purpose of this study was to investigate B7 homolog 3 (B7-H3) expression patterns and define its associations with programmed cell-death ligand 1 (PD-L1), pathological features, and survival in patients with cervical cancer. Patients and Methods: Immunohistochemical staining was used to investigate B7-H3 and PD-L1 expression in tissue microarrays from 552 patients with stage IB1 and IIA1 cervical cancer, including 406 with squamous cell carcinoma and 146 with endocervical adenocarcinoma. Results: B7-H3 was expressed in the tumor cells (TCs) of 32.1% of the samples as well as in the stromal cells of 92.9% of the specimens. B7-H3 was co-expressed with PD-L1 in 21.0% of the samples, while only one or the other was expressed in 41.7% of the samples. B7-H3 expression in TCs was more frequent in squamous cell carcinoma, PD-L1-positive samples, and tissues from patients with lymph node metastasis; moreover, its expression was an independent predictor of shorter survival. Conclusion: B7-H3 positivity in TCs is a promising prognostic biomarker, and targeting B7-H3 alone or in combination with PD-1/PD-L1 may be a potential immunotherapeutic strategy for patients with cervical cancer. Keywords: carcinoma of the cervix, programmed cell-death ligand 1, B7 homolog 3, immunotherapy Introduction Cervical cancer is the third most common cancer in women worldwide. Following the implementation of cervical cancer screening and development of effective preventative vaccines, the overall incidence of cervical cancer has declined during the past decade; 1 however, the relative and absolute incidences of adenocarcinoma are still rising. 2 Most patients with early-stage disease have favorable prognoses; nonetheless, those with advanced or recurrent disease have poor outcomes. In recent years, immunotherapy targeting the immune checkpoint programmed cell-death 1 (PD-1) and its ligand programmed cell-death ligand 1 (PD-L1) has emerged as a novel modality in oncology and has been shown to be effective against a variety of tumor types. The United States Food and Drug Administration has approved the PD-1 inhibitor pembrolizumab for patients with recurrent or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) of ≥1. However, the objective response rate for pembrolizumab was found to be 14.6% in a Phase II study. 3 Therefore, efforts continue to identify new targets and develop novel immunotherapeutic strategies for patients with this disease. B7 homolog 3 (B7-H3), also known as CD276, belongs to the B7 superfamily that also includes PD-L1 and is an immune checkpoint protein that exhibits essential roles in T cells. Notably, B7-H3 has been reported to have both costimulatory and coinhibitory abilities in different tumor microenvironments. 4 Chapoval et al demonstrated that B7-H3 increases the proliferation of CD4+ and CD8+ T cell populations and upregulates IFN-γ production. 5 In contrast, Suh et al showed that B7-H3 is a negative regulator that inhibits T cell proliferation. 6 B7-H3 protein is present at low levels in the liver, colon, and prostate but is rare in normal tissues overall; nevertheless, it is expressed in various types of malignant tissues including lung cancer, 7 colorectal cancer, 8 prostatic cancer, 9 renal cell carcinoma, 10 breast cancer, 11 endometrial cancer, 12 ovarian cancer, 13 gestational trophoblastic neoplasia, 14 and cervical cancer. 15–18 B7-H3 is expressed in tumor cells (TCs) and stromal cells including tumor-associated vascular endothelial cells, fibroblasts, and immune cells. 7 , 19 , 20 Generally, B7-H3 is associated with tumor aggressiveness, unfavorable clinicopathological features, and poor outcomes. It has been shown to promote invasion, migration, and angiogenesis in lung, colorectal, ovarian, and prostate cancers. 21–24 These results suggest that B7-H3 may be able to induce cancer progression and metastasis beyond its ability to modulate tumor immunity. 4 Although B7-H3 expression in cervical cancer has been reported in previous studies, including ours, 12–15 , 18 its association with PD-L1 remains unclear. Furthermore, the numbers of patients included in previous studies were small, particularly those with adenocarcinoma. Therefore, the associations between B7-H3 and histological subtypes as well as with survival outcomes remain unknown. As such, the aims of this study were to explore B7-H3 expression within cervical cancer tissues and to assess the relationship between this expression and PD-L1, clinicopathological features, and patient outcomes. Materials and Methods Study Cohort and Tissue Microarray (TMA) Construction This retrospective study included 552 radical hysterectomy specimens from patients diagnosed with either squamous cell carcinoma of the cervix (N = 406) between January 2012 and December 2015 or usual type endocervical adenocarcinoma (N = 146) between January 2008 and December 2017, at Qilu Hospital of Shandong University (Jinan, China). All patients in this study were diagnosed before 2018; therefore, we used the 2009 International Federation of Gynecology and Obstetrics (FIGO) staging system for carcinoma of the cervix. Considering the excellent odds of survival in patients with stage IA, we included only patients with IB1 and IIA1 disease, for whom the standard treatment was radical hysterectomy with pelvic lymph node dissection and/or para-aortic lymph node sampling or dissection. The following patients were excluded from the study: those with non-usual types of endocervical adenocarcinoma (adenosquamous, mucinous gastric/intestinal, adenoma malignum, serous, clear cell, or endometrioid), those with neuroendocrine carcinoma, those with insufficient data, those who died within 1 month after surgery, and those who received neoadjuvant therapy before surgery. Clinicopathologic data (collected from medical records) included age at diagnosis, tumor size, tumor histology, differentiation grade, depth of invasion, parametrial involvement, lymphovascular space invasion, number of positive lymph nodes, postoperative adjuvant treatment (chemotherapy, chemoradiotherapy, or radiotherapy), date of recurrence or last follow-up, and patient status on the last follow-up date. Representative areas within the tumor tissue were marked on hematoxylin and eosin-stained slides and sampled for the TMA blocks. TMAs with a single 2 mm core per case were constructed using a tissue arrayer (Mini Core, Mitogen, Hertford, UK). This study conformed to the ethical standards set forth in the Declaration of Helsinki and in national and international guidelines and was approved by the Institutional Review Board of Qilu Hospital of Shandong University (approval No. KYLL-2017-560). All investigators signed patient data confidentiality statements, and patient data were only accessible on confidential computers at Qilu Hospital of Shandong University. All patients, upon admission to the hospital, signed consent forms allowing review of their medical records, the use of their tissue samples, and possible publication of associated reports. None of the patients can be identified from their clinical information or images in this retrospective study, and informed consent to determine PD-L1 and B7-H3 expression was not required by the Institutional Review Board of Qilu Hospital of Shandong University. Immunohistochemistry and Assessment Immunohistochemistry was performed using our laboratory protocol as described previously. 14 , 17 , 26 Briefly, 4 μm TMA serial sections were deparaffinized and subjected to heat-induced epitope retrieval with 10 mM sodium citrate (pH 6.0) at 95°C for 20 min. The endogenous peroxidase activity was quenched using a 0.3% hydrogen peroxide solution. TMA sections were incubated with primary antibodies against PD-L1 (dilution 1:200, clone E1L3N, Cell Signaling Technology, Danvers, USA) and B7-H3 (dilution 1:200, clone D9M2L, Cell Signaling Technology, Danvers, USA). Human placental tissues treated with primary antibodies were used as positive controls, while the same tissues without primary antibodies comprised negative controls. All the slides were stained using an automatic immunohistochemistry staining instrument (BOND-III; Leica Biosystems, Wetzlar, Germany) according to the manufacturer’s instructions. PD-L1 was evaluated using the CPS, which was calculated as the sum of the number of PD-L1-stained cells (TCs, lymphocytes, and macrophages) divided by the total number of viable tumor cells, with the quotient multiplied by 100. A CPS of ≥1 was considered indicative of positive PD-L1 expression. Samples were considered positive for B7-H3 when ≥5% of the TCs expressed this protein at any intensity; the 5% cut-off was chosen based on a previous publication. 6 Staining of B7-H3 in stromal fibroblasts, endothelial cells, and immune cells was also recorded. Statistical Analysis The χ2 test was used to determine the association between categorical variables. Relapse-free survival (RFS) was defined as the interval between the date of surgery and that of the detection of the first local, regional, and/or distant relapse. Overall survival (OS) was defined as the time between the date of surgery and that of death from any cause, censoring, or the last follow-up. Survival curves were plotted using the Kaplan–Meier method and compared using the Log rank test. To identify prognostic predictors, univariate and multivariate survival analyses were performed using the Cox proportional hazards regression model, and hazard ratios (HRs) with 95% confidence intervals (CIs) for recurrence and death were calculated. All statistical analyses were conducted using the Statistical Package for the Social Sciences software (version 20.0; IBM Corp., Armonk, NY, USA). A 2-sided P-value <0.05 was considered statistically significant. Results B7-H3 Expression in Cervical Cancer The median age of the 552 patients in this study was 47 years (range, 24–78 years); their clinicopathological characteristics are summarized in Table 1 . A total of 460 patients received postoperative adjuvant treatment, of whom 220 received chemoradiotherapy, 146 received radiotherapy only, and 94 received adjuvant chemotherapy. Table 1 Clinicopathological Characteristics and Expression Patterns of B7-H3 in Patients with Cervical Cancer (N = 552) B7-H3 was expressed by both TCs and stromal cells and exhibited a cytoplasmic/membranous staining pattern ( Figure 1 ). B7-H3 expression was positive in the TCs of 177 samples (32.1%) and in the stromal cells of 513 (92.9%). PD-L1 expression was positive in 51.6% of the samples (285/552), and was detected in TCs, lymphocytes, and macrophages ( Figure 1 ). Representative immunohistochemical staining of B7-H3 in macrophages, endothelial cells, and stromal fibroblasts is shown in Figure 2 . Figure 1 Representative immunohistochemical staining of B7 homolog 3 (B7-H3) and programmed cell-death ligand 1 (PD-L1) in squamous cell carcinoma (SCC) (left column) and adenocarcinoma (AC) (right column) of the cervix. Positive B7-H3 in tumor cells and stromal cells (A and B), negative B7-H3 in tumor cells and positive B7-H3 in stromal cells (C and D), and positive PD-L1 as defined by a combined positive score of ≥1 (E and F). Figure 2 Representative immunohistochemical staining of B7 homolog 3 (B7-H3) in macrophages, endothelial cells, and stromal fibroblasts. B7-H3 expression in (A) macrophages (red arrowheads) and (B) corresponding CD68+ macrophages (red arrowheads); (C) endothelial cells (blue arrowheads); (D) stromal fibroblasts (green arrowheads) and endothelial cells (blue arrowhead). Association Between B7-H3 Expression in TCs and Clinicopathological Parameters The associations between B7-H3 expression in TCs, PD-L1, and clinicopathologic characteristics are presented in Table 1 . B7-H3 positivity in TCs was significantly more frequent in squamous cell carcinoma than in adenocarcinoma (36.0% vs 21.2%), and in patients with lymph nodal metastasis than in those without (40.5% vs 29.9%). One hundred and sixteen samples (21.0%) exhibited co-expression of B7-H3 and PD-L1, 206 (37.3%) were double negative, and 230 (41.7%) were positive for either PD-L1 or B7-H3 alone. Additionally, B7-H3 positivity in TCs was observed more frequently in PD-L1-positive samples than in PD-L1-negative counterparts (40.7% vs 22.8%). No statistically significant differences were observed between B7-H3 in stromal cells and PD-L1 expression, nor were there significant associations between B7-H3 expression in stromal cells and clinicopathological parameters (data not shown). In addition, PD-L1 positivity was more frequent in squamous cell carcinoma than in adenocarcinoma (58.4% vs 32.9%, P < 0.001) and in poorly-differentiated tumors compared to well-to-moderately differentiated tumors (55.7% vs 43.5%, P = 0.007). Patients with PD-L1-positive tumors and those with positive B7-H3 expression in TCs were more likely to have received postoperative adjuvant treatment than patients with PD-L1-negative (89.8% vs 76.4%, P < 0.001) or B7-H3-negative tumors (88.1% vs 81.1%, P = 0.038). Associations of B7-H3 Expression in TCs with Patient Outcomes After a median follow-up of 55 months (range, 7–114 months), 54 patients (9.8%) relapsed and 61 (11.1%) died of any cause. Kaplan–Meier survival analyses showed that patients who had B7-H3-positive TCs had a shorter RFS and OS ( Figure 3 ). In univariate analysis, B7-H3 positivity in TCs, FIGO stage IIA1, parametrial involvement, deep invasion (≥1/2), and lymph node metastasis were associated with a shorter RFS and OS ( Table 2 ). In multivariate analysis, B7-H3 positivity in TCs was a predictor of shorter RFS (HR 2.1, 95% CI 1.2–3.6, P = 0.006) and OS (HR 1.8, 95% CI 1.1–3.0, P = 0.023), independent of FIGO stage or lymph nodal metastasis ( Table 3 ). Positive PD-L1 or B7-H3 expression in stromal cells was not associated with patient outcomes. Table 2 Univariate Analysis of Relapse-Free and Overall Survival Among Patients with Cervical Cancer (N = 552) Table 3 Multivariate Analysis of Relapse-Free and Overall Survival Among Patients with Cervical Cancer (N = 552) Figure 3 Kaplan–Meier curves showing the (A) relapse-free survival (RFS) and (B) overall survival (OS) of patients with cervical cancer according to B7 homolog 3 (B7-H3) expression in tumor cells. Discussion To the best of our knowledge, ours is the first study to investigate B7-H3 expression and its association with PD-L1, clinicopathological features, and survival in a large cohort of patients with cervical cancer. We observed tumoral B7-H3 expression in 32.1% of the patients; this protein was also expressed in the stromal cells of most patients. Moreover, B7-H3, PD-L1, or both together were expressed in 62.7% of the patients. Additionally, B7-H3 positivity was significantly associated with the histologic subtype, lymph node metastasis, and PD-L1 positivity, and was an independent predictor of shorter RFS and OS. These findings support the notion that B7-H3 is a prognostic marker as well as a therapeutic target (either via monotherapy or combined with PD-1/PD-L1 blockade) in patients with cervical cancer. Studies investigating B7-H3 expression in cervical cancer are relatively rare. Brustmann et al found that B7-H3 was expressed in most of the 64 samples obtained from patients with cervical squamous cell carcinoma. The protein was expressed in the endothelial cells of the tumor-associated vasculature as well as in epithelial TCs, where its high expression was observed more frequently in patients with FIGO stage IB disease than in those with stage IA; however, its expression was not associated with survival. 25 In a study of 108 patients, Huang et al demonstrated that B7-H3 was expressed in the TCs of 72% of their cervical cancer samples; the protein was highly expressed in the stromal compartments, and patients with a high level of B7-H3 expression in TCs had worse prognoses. 15 In our previous study of a small cohort of 60 patients, we found that B7-H3 positivity correlated with shorter disease-free survival. 16 Consistent with previously published data, our present study showed that B7-H3 expression was observed in both TCs and stromal cells in patients with cervical cancer, and that its expression in TCs correlated with shorter survival. B7-H3 was expressed more frequently in squamous cell carcinoma than in adenocarcinoma in our cohort. Similarly, Heeren et al demonstrated that squamous cell carcinomas were more frequently positive for PD-L1 than were adenocarcinomas. 27 No association between B7-H3 expression and histologic subtypes was found in previous studies; this discrepancy may be attributed to their small number of patients with adenocarcinoma. Our study is the first to describe the differential distributions of B7-H3 across histologic subtypes; however, further studies are necessary to confirm our results. While the expression of PD-L1 and B7-H3 in cervical cancer has previously been reported, 15 , 16 , 25 , 27–29 none of these studies investigated the potential correlations between PD-L1 and B7-H3 expression. In our study, we observed these proteins’ co-expression in 21.0% of samples, with another 41.7% containing either one or the other. Moreover, we found that B7-H3 positivity was correlated with PD-L1 expression. Similar results have been reported in lung cancer and upper tract urothelial carcinoma. 30–32 For example, Altan et al observed that B7-H3 and PD-L1 were co-expressed in 17.6% of patients with non-small cell lung cancer. 30 Parra et al demonstrated that PD-L1 expression was positively correlated with that of B7-H3 in the TCs of 142 lung adenocarcinomas. 31 Koyama et al also found that B7-H3 positivity was significantly correlated with PD-L1 positivity in patients with upper tract urothelial carcinoma, and their combined expression was significantly associated with poor survival outcomes. 32 These data indicate that B7-H3 and PD-L1 play nonredundant and somewhat complementary roles in tumor immune evasion, which support the rationale for developing combined therapies that target both proteins. In the study by Yonesaka et al, the dual blockade of B7-H3 and PD-L1 in a murine cancer model yielded a synergistic antitumor effect compared with that when inhibiting either alone. 33 Enoblituzumab (MGA271), an Fc-optimized monoclonal antibody that selectively targets B7-H3, is currently being evaluated either as a monotherapy or in combination with the PD-1 inhibitor pembrolizumab in Phase 1 studies of patients with B7-H3-expressing cancers (NCT02475213, NCT01391143). Our results support targeting B7-H3 alone or in combination with PD-1/PD-L1 blockade as an immunotherapeutic strategy for the treatment of B7-H3-expressing cervical cancer. Further studies are warranted to identify this protein’s cognate receptor(s), the modulation of its expression, and its immunomodulatory roles; this will assist in the clinical development of effective immunotherapeutic B7-H3 modulators to treat cancer. The strengths of our study were that we restricted our analysis to stage IB1/IIA1 squamous cell carcinoma and usual type endocervical adenocarcinoma and that our sample size was relatively large (N = 552). However, our study also had limitations. First, it was retrospective in nature and was therefore subject to inherent unavoidable biases. Second, given intra-tumoral heterogeneity, assessment of immunohistochemical staining using TMAs may not have accurately represented the entire tumor considering marker expression. Finally, the criteria for B7-H3 positivity have not been defined, and the cut-off point we used to stratify positive versus negative expression was based on a previous publication describing a prostate cancer study. 6 Additional studies from independent cervical cancer cohorts will be required to determine the optimal expression cut-offs for B7-H3 in this particular disease. Conclusion B7-H3 was expressed in the TCs and stromal cells of cervical cancer tissues. The expression of this protein in TCs was more frequent in squamous cell carcinoma, samples that were positive for PD-L1, and samples from patients with lymph node metastasis; moreover, its expression was an independent predictor of poor survival. The frequent expression of B7-H3, PD-L1, or both together supports the development of anti-B7-H3 therapies alone or in combination with PD-1/PD-L1 blockade to treat patients with cervical cancer. Further studies are warranted to validate our results and explore other immunotherapeutic strategies against cervical cancer that include B7-H3 inhibition. Funding This work was supported by grants from the National Key R&D Program of China (2016YFC1302900 and 2016YFC0902901), National Natural Science Foundation of China (NSFC, 81572559), Key Research Project of Shandong Province (2017CXGC1210), Science and Technology Development Plan of Tai’an (2016NS1099), and Medical and Health Technology Development Plan of Shandong Province (202005010853). Disclosure

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing figo

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned figo in 1 CB Insights research brief, most recently on Mar 2, 2021.

Expert Collections containing figo

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

figo is included in 6 Expert Collections, including Banking.



620 items


Fintech 250

248 items


Capital Markets Tech

1,300 items

Companies in the capital markets tech space are providing software and/or services for investment banks, hedge funds, investment managers, and so forth. Companies included use technology across the front, middle, and back-offices and streamline all pre- and post-trade operations.


SMB Fintech

1,073 items


Automation in Banking

380 items

Startups providing solutions to banks to automate processes and operations.



10,749 items

Excludes US-based companies

figo Patents

figo has filed 1 patent.

The 3 most popular patent topics include:

  • Electronic health records
  • Health informatics
  • Image processing
patents chart

Application Date

Grant Date


Related Topics



Health informatics, Electronic health records, Image processing, Military insignia, Medical terminology


Application Date


Grant Date


Related Topics

Health informatics, Electronic health records, Image processing, Military insignia, Medical terminology



figo Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

figo Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.